2016) Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. European Respiratory Journal, 48 (4).
Full-text articles assessed for eligibility (n =27)
Full-text articles excluded (n = 15)  Combined results for adolescents and adults (n=2)  Different outcomes measurement (n=10)  Severe asthma population (n=3)
Records identified through database searching (n =1054)
Records excluded that did not study the association between obesity and asthma severity (n = 994)
Studies included in qualitative synthesis (n =12) plus analysis of three additional cohorts
Additional records identified through other sources (n =6)
Studies met all inclusion criteria and included in meta-analysis (n =14)
Article excluded because of Low quality score (n=1) All three studies are retrospective cohort studies. In BREATHE, children and adolescents with physician-diagnosed asthma were recruited either through primary or secondary clinics. In PACMAN paediatric users of asthma medication were selected through Dutch community pharmacies. In this cohort, children aged 4-12 years with at least 2 years of medication history available and at least 3 prescriptions for any asthma drug within the last 2 years and at least 1 prescription in the last 6 months were selected from pharmacies in different regions in the Underweight children were not included in the logistic regression analyses. The differences in baseline characteristics of children with and without missing values in the three cohorts were compared. The frequency of baseline characteristics in the different BMI percentile categories were stratified by gender. The associations of obesity with poor asthma control and/or risk of exacerbations among obese girls and boys versus non-obese peers was estimated using binary logistic regression in univariate and multivariate ways to calculate crude and adjusted odd ratios (ORs) with 95% confidence intervals (CIs). In subgroup analysis, the effect of age on this association was tested in stratified analyses in three different age categories 4-6, 6.01-12.99 and 13-18 years. In a sensitivity analysis, the associations between obesity versus normal weight and poor asthma control and/or risk of exacerbations among obese girls and boys were also evaluated. Age, eczema, hay fever, pet's exposure, breast feeding, family history of asthma and family history of allergy, asthma in sibling and race/ethnicity were considered as potential confounders in these associations.
P-values of 0.05 were used to assess the statistical significance of main effect associations. We used SPSS 23.0 to analysis the data.
Results:
Data were available for 1,318 children and adolescents ages 4-18 years of the BREATHE cohort, 648 children ages 4-12 year of the PACMAN cohort and 422 children and adolescents ages 4-17 years of the PAGES cohort. The baseline characteristics of the three study populations are presented in Table S2 . The incidence of obesity was 13% in BREATHE, 11% in PACMAN and 15% in PAGES. Poor asthma control was higher in PAGES (64%) compared with PACMAN (40%).
Asthma exacerbations (either ED visits/asthma related hospitalization or OCSs dispensing) rates were higher in BREATHE (27%) and PAGES (40%) compared with PACMAN (10%).
We found statistically significant differences in baseline characteristics of the patients with and without data on BMI which was more pronounced in BREATHE and PAGES. Children in BREATHE and PAGES cohorts with missing data on BMI have remarkably less asthma exacerbations (both hospitalization due to asthma and OCSs use) compared with those that have data on BMI ( Table S3 ).
The frequency of the baseline characteristics in the different BMI percentile categories was shown in Table S4 . As shown, no significant differences between obese vs. non-obese children in different baseline characteristics were observed neither in girls nor in boys in the BREATHE cohort. In the PACMAN cohort, there were statistically significant differences between obese and non-obese peers in different baseline characteristics e.g. age (p=0.003), race (p=0.03) and exacerbations (p<0.001) in girls and family history of asthma in boys (p=0.01). In the PAGES cohort, significant difference between obese and non-obese children was shown only in girls with eczema (p=0.05) and in boys with poor asthma control (p=0.04).
As shown in Table S5 , when boys and girls were combined, there was no association between obesity and poor asthma control in either population with an opposite direction in PACMAN and PAGES cohorts (OR: 0.95, 95% CI: 0.54-1.67 and OR: 1.66, 95% CI: 0.70-3.94, respectively).
Obese girls in the PACMAN cohort were more likely to have poor asthma control compared to nonobese girls while in the PAGES cohort obese boys were at increased risk of poor asthma control than non-obese boys. No asthma control data was available for the BREATHE cohort.
There was an increased risk for exacerbations (both ED visits and OCSs use) among obese girls compared to non-obese girls in the PACMAN population (OR: 4.03, 95% CI: 1.06-15.38 and OR:
5.66, 95% CI: 1.37-23.31, respectively) but not in the other populations. When boys only and when boys and girls were combined, there was no significant association between obesity and risk for exacerbations (Table S5) .
When stratifying logistic regression analysis by age, the results showed no difference between different age categories (Table S6) .
A sensitivity analysis was conducted to evaluate the association between obesity and outcomes in obese versus normal-weight children and the results showed no significant differences compared with the results for these associations in obese versus non-obese peers (data not shown).
Actual confounders in the association between obesity and asthma severity were the following:
in BREATHE, age, rhinitis, and family history of asthma, in PACMAN, age, eczema, breast feeding, ethnicity/race, family history of asthma and allergy, and in PAGES, age, eczema, rhinitis and family history of allergy.
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( The treatment step was modified from BTS guidelines as follows: step 1 is use of short-acting beta agonists (SABAs) as needed; step 2 is the step 1 plus regular inhaler corticosteroids (ICSs); step 3 is the step 2 plus regular long-acting beta agonists (LABAs); and step 4 is the step 3 plus oral leukotriene receptor antagonists (LTRAs). b At least one asthmatic parent. c At least one allergic parent. d At least on asthmatic sibling. ᵠ Asthma exacerbations defined as either ED visits/hospitalization due to asthma or OCSs use 
